Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
This study aimed to assess the Withania coagulans fruit extract's effects on growth and haematological parameters of Labeo rohita. Healthy fish (n = 120) were divided in four groups. Experimental diet was prepared with different extraction of W. coagulans (0%, 1%, 1.5% and 2%). Diet was provided for eight weeks to all groups except the control group which fed on basal diet. The 1.5% and 2% W. coagulans extracts lead improvement in feed conversion ratio and specific fish growth rate; haematological parameters in fish group fed with 2% of W. coagulans showed increased in WBC, RBC, Hb, MCHC, PCV. The values of plasma proteins and lysozyme activity were higher in the experimental group compared control group. Fish fed with W. coagulans extracts showed increased of immunity and less mortality respect to others. It suggested that W. coagulans could be considered valuable support for the improve growth and immunity in Labeo rohita.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/14786419.2022.2089139 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Genetic factors associated with the co-occurrence of endometriosis with antiphospholipid syndrome (Review).
Exp Ther Med
October 2025
Section of Molecular Pathology and Human Genetics, Department of Internal Medicine, School of Medicine, University of Crete, 71003 Heraklion, Greece.
Immune-related factors may serve an important role in the development of endometriosis, considering the occurrence of substantial abnormalities in the immune system of women with endometriosis, including reduced T-cell reactivity and natural killer cell cytotoxicity, as well as increased numbers and activation of peritoneal macrophages. Moreover, women suffering from endometriosis are at a higher risk for developing various autoimmune diseases as comorbidities of endometriosis. Recent epidemiological data demonstrate that patients with endometriosis have a significantly higher risk (2.
View Article and Find Full Text PDFPRMT1-Mediated PARP1 Methylation Drives Lung Metastasis and Chemoresistance via P65 Activation in Triple-Negative Breast Cancer.
Research (Wash D C)
September 2025
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype, characterized by a high propensity for metastasis, poor prognosis, and limited treatment options. Research has demonstrated a substantial correlation between the expression of protein arginine N-methyltransferase 1 (PRMT1) and enhanced proliferation, metastasis, and poor outcomes in TNBC. However, the specific role of PRMT1 in lung metastasis and chemoresistance remains unclear.
View Article and Find Full Text PDFCongenital disorders of glycosylation (CDG) are a heterogeneous group of inherited metabolic diseases (IMD) characterized by defects in the synthesis and modification of glycoproteins and glycolipids. One of these disorders is ATP6AP1-CDG, a rare X-linked disease with approximately 30 cases reported so far. Symptoms associated with ATP6AP1-CDG include immunodeficiency, liver dysfunction, and neurological manifestations.
View Article and Find Full Text PDFSLC16A3 (MCT4) expression in tumor immunity and Metabolism: Insights from pan-cancer analysis.
Biochem Biophys Rep
June 2025
The Affiliated Traditional Chinese Medicine Hospital, Guangzhou Medical University, Guangzhou, Guangdong Province, China.
Background: SLC16A3, a highly expressed H + -coupled symporter, facilitates lactate transport via monocarboxylate transporters (MCTs), contributing to acidosis. Although SLC16A3 has been implicated in tumor development, its role in tumor immunity remains unclear.
Methods: A pan-cancer analysis was conducted using datasets from The Cancer Genome Atlas, Cancer Cell Line Encyclopedia, and Genotype-Tissue Expression projects.
Immunotherapy and Targeted Therapies in Sarcoma: Proposed Synergy with Combination Treatment.
J Immunother Precis Oncol
August 2025
Department of Medicine, Sylvester Comprehensive Cancer Center/University of Miami, Miami, FL, USA.
The combination of targeted therapies and immunotherapies for advanced and metastatic sarcomas has been proposed owing to the enhanced effect of antiangiogenic therapies on the tumor microenvironment. We found eight studies published to date assessing the effectiveness of combined multitargeted vascular endothelial growth factor (VEGF)-tyrosine kinase inhibitors with immune checkpoint inhibitors (ICIs) in sarcoma. It is difficult to draw conclusions owing to limited data and primarily single-arm studies, although initial literature appears promising and requires further study.
View Article and Find Full Text PDF